UFT Plus Calcium Folinate/Irinotecan in Golorectal Cancer

ONCOLOGY

Volumn 13, Issue 7 SUPPL., 1999, Pages 51-54

  Twelves, Chris ^a  

^a IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CAMPTOTHECIN; DNA TOPOISOMERASE; FLUOROPYRIMIDINE; FLUOROURACIL; FOLINATE CALCIUM; GLYCOPROTEIN P; IRINOTECAN; ORZEL; SINGLE STRANDED DNA; TEGAFUR; UNCLASSIFIED DRUG; URACIL;

ADJUVANT THERAPY; ADULT; ADVANCED CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; COLORECTAL CANCER; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DRUG INFORMATION; DRUG INFUSION; DRUG MEGADOSE; DRUG TOLERANCE; HUMAN; INTRAVENOUS CATHETER; INTRAVENOUS DRUG ADMINISTRATION; MINIMUM INHIBITORY CONCENTRATION; NEUTROPENIA; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; UNITED STATES;

ADOLESCENT; ANTINEOPLASTIC AGENTS, PHYTOGENIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; COLORECTAL NEOPLASMS; DNA TOPOISOMERASES, TYPE I; DRUG THERAPY, COMBINATION; HUMANS; LEUCOVORIN; TEGAFUR; TREATMENT OUTCOME; URACIL;

EID: 0032769059     PISSN: 08909091     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Fujii S, Kitano S, Ikenaka K, et al: Studies on coadministration of uracil or cytosine on antitumour activity of FT-207 or 5-FU derivatives. Can To Kagaku Ryoho 16:377-384, 1979.
2. Tagacki T, Furue H, Koyama Y, et al: Phase I study of UFT. Can To Kagaku Ryoho 7:966- 972, 1980.
3. Pazdur R, Lassere Y, Rhodes V, et al: Phase II trial of uracil and tegafur plus oral leucovorin: An effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12:2269-2300, 1994.
4. Creemers GJ, Lun D, Verweiij J: Topoisomerase I inhibitors: Topotecan and irinotecan. Cancer Treat Rev 20:73-96, 1994.
5. Giovanella BC, Stehlin JS, Wall ME, et al: DNA topoisomerase 1-targeted chemotherapy of human colon cancer in xenografts. Science 246:1046-1048, 1989.
6. Chen AY, Yu C, Potmesil M et al: Camptothecin overcomes MDRI-mediated resistance in human KB carcinoma cells. Cancer Res 51:6039-6044, 1991.
7. Abigerges D, Chabot GG, Armand JP, et al: Phase I pharmacokinetic studies of the camptothecin analogue irinotecan, administered every 3 weeks in cancer patients. J Clin Oncol 13:210- 221, 1995.
8. Catimel G, Chabot GG, Guastella JP, et al: Phase I and pharmacokinetic study of irinotecan (CPT-11) administered daily for three consecutive days every 3 weeks in patients with advanced solid tumours. Ann Oncol 6:133-140, 1995.
9. De Forni M, Bugart R, Chabot GG, et al: Phase I and pharmacokinetic study of the camptothecin derivative irinotecan, administered on a weekly schedule in cancer patients. Cancer Res 54:4347-4354, 1994.
10. Rothenberg ML, Eckardt JR, Kuhn JG, et al: Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 14:1128-1135, 1996.
11. Saltz LB, Kanowitz J, Kemeny N, et al: Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumours. J Clin Oncol 14:2959-2967, 1996.
12. Sasaki Y, Ohtsu A, Shimada Y, et al: Simultaneous administration of CPT-11 and fluorouracil: Alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 86:1096- 1098, 1994.
13. Saltz L, Shimada Y, Khayat D: CPT-11 (irinotecan) and 5-fluorouracil: A promising combination for therapy of colon cancer. Eur J Cancer 32(suppl 3):S24-S31, 1996.